Drug Profile

Research programme: STAC-BBB based therapeutics - Astellas Gene Therapies/SangamoTherapeutics

Latest Information Update: 01 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sangamo Therapeutics
Developer Astellas Gene Therapies; Sangamo Therapeutics
Class Proteins; Transcription factors
Mechanism of Action DNA-binding protein modulators; Genetic transcription modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

31 Dec 2024 Preclinical trials in Neurological disorders in USA (Parenteral) prior to December 2024
19 Dec 2024 Astellas Gene Therapies and Sangamo Therapeutics enters into a licensing agreement for STAC-BBB to develop genomic medicines to treat certain neurodegenerative diseases
19 Dec 2024 Early research in Neurological disorders in USA (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com